Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900526 | 0.83 | — | — | |
| SCHEMBL1019858 | 0.78 | METAP2 (0.44) | ALDH1A1METAP2 | |
| SCHEMBL9324607 | 0.74 | METAP2 (0.44) | ALDH1A1METAP2 | |
| SCHEMBL3173313 | 0.74 | KMT2A (0.44) | ALDH1A1METAP2 | |
| SCHEMBL4017134 | 0.74 | METAP2 (0.44) | METAP2 | |
| SCHEMBL4559345 | 0.73 | KMT2A (0.42) | ALDH1A1METAP2 | |
| SCHEMBL3755870 | 0.70 | — | — | |
| SCHEMBL3140312 | 0.69 | — | — | |
| SCHEMBL9609757 | 0.68 | TSHR (0.56) | TRPA1ALDH1A1TSHR | |
| SCHEMBL679626 | 0.68 | TSHR (0.56) | TRPA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735302-B1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090136551-A1 | Substituted Dicyanoalkanes For Combating Animal Pests | BASF AKTIENGESELLSCHAFT (DE) | 2009-05-28 | — | — | US | disclosed |
| US-7521462-B2 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1912958-A1 | SUBSTITUTED MALONONITRILE COMPOUNDS FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2007044796-A2 | PYRIDAZINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007017414-A1 | SUBSTITUTED MALONONITRILE COMPOUNDS FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2007-02-15 | — | — | WO | disclosed |
| EP-1735302-A1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2005092885-A1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136551-A1 | Substituted Dicyanoalkanes For Combating Animal Pests | DDT, AAK1, DCLK3 | TRPA1 174/4885ALDH1A1 756/4885TSHR 3313/4885 |
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | SLC18A2, SLC6A2, SLC6A3 | TRPA1 1266/4885ALDH1A1 362/4885TSHR 429/4885 |
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | TRPA1 2554/4885ALDH1A1 988/4885TSHR 4703/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | TRPA1 4802/4885ALDH1A1 827/4885TSHR 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.